The association between sensitizing mutations in the EGFR gene and response to treatment has led to recommendations by major oncology organizations that NSCLC tumors should be tested for the presence of these mutations before treatment [8-10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.